eCommons@AKU
Section of Pulmonary & Critical Care

Department of Medicine

July 2019

Visual and treatment outcomes of tubercular
uveitis: a prospective case series from a referral
hospital in Pakistan
Muhammad Ishaq Ghauri
Jinnah Medical College Hospital, Karachi, Pakistan.

Nousheen Iqbal
Aga Khan University, nousheen.iqbal@aku.edu

Syeda Urooj Riaz
Jinnah Medical College Hospital, Karachi, Pakistan.

Muhammad Irfan
Aga Khan University, muhammad.irfan@aku.edu

Ajeet Kumar
Jinnah Medical College Hospital, Karachi, Pakistan.
See next page for additional authors

Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_med_pulm_critcare
Part of the Pulmonology Commons
Recommended Citation
Ghauri, M. I., Iqbal, N., Riaz, S. U., Irfan, M., Kumar, A., Mukarram, M. S. (2019). Visual and treatment outcomes of tubercular uveitis:
a prospective case series from a referral hospital in Pakistan. BMC research notes., 12(1), 404-404.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/150

Authors

Muhammad Ishaq Ghauri, Nousheen Iqbal, Syeda Urooj Riaz, Muhammad Irfan, Ajeet Kumar, and Muhamad
Shariq Mukarram

This article is available at eCommons@AKU: https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/150

(2019) 12:404
Ghauri et al. BMC Res Notes
https://doi.org/10.1186/s13104-019-4432-8

BMC Research Notes
Open Access

RESEARCH NOTE

Visual and treatment outcomes of tubercular
uveitis: a prospective case series from a referral
hospital in Pakistan
Muhammad Ishaq Ghauri1, Nousheen Iqbal1,2* , Syeda Urooj Riaz1, Muhammad Irfan2, Ajeet Kumar1
and Muhamad Shariq Mukarram1

Abstract
Objective: Pakistan is the fifth highest TB burden country. Tuberculous uveitis (TbU) is a form of extrapulmonary TB,
that is not uncommon in high burden country but very limited data is available on its outcome. The aim of the study
is to assess the outcome of TbU with anti-tuberculous treatment (ATT).
Results: A prospective study was conducted at Jinnah Medical College Hospital (JMCH) Karachi, Pakistan from July
to December 2017. Patients with suspected TbU were started on standard ATT chemotherapy for 12 months. Their
response was assessed via slit lamp examination and visual acuity at 1, 3, 6 and 12 months of treatment. Forty patients
with probable TbU were treated with ATT, mean age was 36 ± 3 years and 24 (60%) were females. Around 26 (65%)
had Monteux test of 15 mm or more. History of TB contact was positive in 24 (60%) and 12 (30%) had previous history
of TB. All patients complained for blurring of vision and floaters. Posterior uveitis seen in 36 (90%) of patients. Complete response achieved in 32 (80%) after ATT while 6 (14%) had changed in inflammation and 2 (6%) had no benefit.
Keywords: Ocular TB, Uveitis, Anti tuberculous treatment, Tuberculous uveitis
Introduction
Tuberculosis (Tb) is a leading cause of mortality and morbidity worldwide, especially in South East Asia regions
which carries high burden of Tb. Tb can involve any part
of the body, it causes both pulmonary and extrapulmonary diseases. Tb is preventable and completely curable
disease despite of this an estimated 1.3 million deaths
among HIV negative caused in 2017 [1]. Pakistan is the
fifth highest Tb burden country worldwide.
Tuberculous uveitis (TbU) is a rare entity of extra pulmonary Tb where uveal track involvement is common. It
causes granulomatous anterior uveitis, disseminated choroiditis with vitritis, and cystoid macular edema [2]. TbU
sometimes manifest with non-specific features ranging
from non-granulomatous anterior uveitis to occlusive
retinal vasculitis [3]. Prevalence of TbU is variable in
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different parts of world, being more common in south
East Asia. A study from Pakistan showed that granulomatous diseases are the frequent cause of uveitis likely
because of high burden of Tb [4].
Tuberculous uveitis is a great mimicker of many diseases [5]. Diagnosis is usually presumptive because of
variable presentation and difficulty in obtaining culture
and histopathology tissues [6]. Diagnosis requires a high
index of suspicion and is made by exclusion of other
causes of uveitis like sarcoidosis and autoimmune diseases. The diagnosis of TbU can be confirmed by finding
caseating granuloma, acid-fast bacilli on histopathology
of ocular tissues and on isolation of the organism on AFB
culture or by Nucleic acid amplification tests. Usually
histopathologic specimens reveals a paucity of organisms [7]. The absence of pulmonary Tb does not rule out
the possibility of ocular Tb, as majority of patients with
extrapulmonary Tb have no evidence of active pulmonary TB [2, 8].
Tuberculous uveitis is treated with standard antituberculous therapy (ATT), 2 months of intensive phase
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followed by 10 months of continuous phase combined
with systemic corticosteroids till clinical response is seen
then tapered off [2]. There is paucity of data from our
country on TbU outcomes likely because of underreporting, so this study was aimed to assess the effect of ATT in
patients with TbU.

Main text
Methods

An observational prospective study was conducted on
patients with TbU at JMCH Karachi, Pakistan from July
to December 2017. JMCH is a 500 bed teaching hospital
spread over 6 acres of land in Korangi, Karachi Pakistan.
TbU patients were referred for treatment after TBU diagnosis by an ophthalmologist from Layton Rahmatullah
Benevolent Trust (LRBT). LRBT is a charitable eye hospital and Pakistan’s largest non-governmental organization
established in 1984. These patients presented at LRBT
with complain of blurring of vision, photophobia, pain,
redness, floaters or photophia. Patients with suspected
of uveitis underwent detailed history, general and slit
lamp examination. Then they were classified according
to standardization of Uveitis Nomenclature (SUN) workshop [9] classification into anterior, Intermedia and posterior uveitis. TB uveitis was defined as an unexplained
uveitis after thorough diagnostic workup, and/or ocular
abnormalities compatible with TB, and/or abnormalities
on chest radiology compatible with TB.
The patient were also inquired about history of fever,
weight loss, history of Tb contact in family, previous history of Tb and associated symptoms. A detailed
physical examination was done. All patients were investigated at baseline with chest xray, ESR and Montoux test
(MT). Patients with TbU were started on ATT (usually
2 months of rifampicin, isoniazid, pyrizinamide, and ethambutol followed by months of rifampicin and isoniazid for total of 1 year duration). Clinical response was
assessed by ophthalmologist at LRBT through slit lamp
examination and visual acuity at 1, 3, 6 and 12 months
followup. Informed consent was obtained from all
patients or the attendant next of kin. JMCH ethical
review committee approved study protocol before the
commencement of the study. All data was collected on
predesigned performa.
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and outcome of uveitis that included change in inflation
complete resolution and no change was done.
Results

A total of 40 cases of TbU was referred to our center
for treatment during the study time period. Mean age
was 36 ± 3 years, 24 (60%) were female and 24 (60%) of
patient had a family history of Tb. Blurring of vision
and floaters was reported in 40 (100%) of patients followed by decrease vision and eye redness (Table 1).
Patients with decrease vision had visual acuity of 6/18
and 6/36 at the start of treatment and at the end of
treatment visual acuity corrected to 6/6 in all of these
patients.
Abnormal chest x-ray finding was present in 12
(30%) of patients, which included nodular infiltrates
in 6 patients, upper lobe cavitation in 2 patients and 4
patients had bilateral hilar lymphadenopathy. Steroids
were received by 3 (7.5%) patients where there was evidence of acute vitritis suggested by an ophthalmologist.
Prednisolone was given in a dose of 1 mg/kg given for
3 weeks, then tapered off, according to the response to
the treatment. We found posterior uveitis as the commonest form of TbU (90%). After taking 12 months of
standard ATT 32 (80%) of patients had complete resolution of symptoms, 14% had partial resolution while
the 2 (6%) had no improvement on treatment (Table 2).
Table 1 Baseline characteristics of patients with TbU
Demographics

Frequency (n = 40)

Mean age

36 ± 3 years

Gender
Male

16 (40%)

Female

24 (60%)

Previous history of TB*

12 (30%)

Family history of TB

24 (60%)

Montoux test (mm)
< 15

14 (35%)

> 15

26 (65%)

ESR (mm)
< 60

10 (25%)

> 60

30 (75%)

Symptom

Statistical analysis

Redness of eye

24 (60%)

All analyses were conducted by using the SPSS (Release
19.0, standard version, copyright © SPSS; 1989–2002).
A descriptive analysis was performed for demographic
features presented as mean ± SD for quantitative variable that is age. Number (percentage) for qualitative
variables that is, gender, history of TB, type of uveitis

Eye pain

6 (15%)

Photophobia

12 (30%)

Blurred vision

40 (100%)

Dark, floating spots in field of vision (floaters)

40 (100%)

Decreased vision

24 (60%)

* Received prior ATT
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Table 2 Type and outcome of Tb uveitis among study
population
Type of uveitis

Percentage

Pan uveitis

10% (4)

Anterior uveitis

0%

Intermediate uveitis

0%

Posterior uveitis

90% (36)

Outcome

Frequency

Resolved

32 (80%)

Change in inflammation

6 (14%)

No change

2 (6%)

Discussion

In this study, we found that posterior uveitis is the commonest TbU presentation in our patients. Overall, our
patient population had a good clinical response and
complete recovery on standard ATT. We found posterior
uveitis in 90% of our patients, which is similar to the data
from India [5, 10]. However, data from developed countries is different, a study from the Netherlands exclusively
studied TbU and found Panuveitis in 51.5%, followed by
posterior uveitis 30.3% [11]. Another study from the UK
found chronic Panuveitis as commonest TbU [3] may be
because of difference of population and regions.
Many patients also had no history of pulmonary or
extrapulmonary Tb other than uveitis [2] as seen in our
patients where only few patients had an abnormal Chest
x ray which was found on routine work-up with no complaints of cough and sputum production. As Pakistan is a
Tb endemic country we found that majority patient had
a positive TB contact history, which can be an important
clue in such patients when suspecting TbU as seen previously in a study from Iraq [12].
Tuberculin skin testing TST or MT was done in all
patients and was found > 15 mm induration in the majority of patients of TbU. These results are similar to the
study published from Iraq, where they also found significant high induration in ocular TB [13]. However, this
testing has limitation in developing countries as MT is
positive in the general population. Along with MT we
also found higher ESR in our patients. Complete recovery
seen in 80% of our patients compared to previous studies
where the success rate was 70%, 70% and 60% respectively
[3, 11, 14]. While all patients had favorable outcomes
with no recurrence of disease in a study from Iraq [13].
Two of our patients had no response to treatment that
may be because of underlying fibrosis or delayed in seeking medical treatment. Three of our patients received
corticosteroids with signs of acute vitritis. The use of systemic steroids is controversial [15] they are usually added

to treat inflammation and macular edema [16]. The posterior uveitis was seen commonly in our study followed
by pan uveitis. This is reported to be commonest form of
uveitis from India in TB uveitis [2, 5] while study from
Saudia, Italian and Swiss center showed pan uveitis followed by posterior uveitis in presumed TbU [8, 17].
Conclusion

In high burden countries, the TbU should be suspected
among patients presenting with symptoms of blurring of
vision, floaters, decrease vision and eye redness, treatment with ATT has a favorable outcome. It is important
to diagnose TbU timely to prevent permanent damage
and visual loss. Although it remains difficult to diagnose,
early recognition of the correct diagnosis and specific
therapy avoids recurrences, improves visual acuity and
intra-ocular inflammation.

Limitations
This study showed TbU experience in term of its treatment outcome. However, it has some limitations, (1) it’s
a single center study, (2) limited number of patients, (3)
there is always limitation in diagnosing TbU, diagnosis was based on history and examination while GenXpert testing was not done. Large multicenter studies are
required to study further patient characteristics and clinical response in Tb endemic countries like Pakistan.
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